Skip to main content
Premium Trial:

Request an Annual Quote

Sirna Revenues Down for Q4 Amid Narrowed Net Loss

NEW YORK, Feb. 5 (GenomeWeb News) - Sirna Therapeutics, of Boulder, Colo., reported $420,000 in revenues for the quarter, down slightly from the prior year period, amid narrowed net losses.


The company, which changed its name from Ribozyme last April to reflect its new focus on siRNA-based therapeutics, reported net losses of $6.1 million for the quarter ended Dec. 31, down from $10,342.


R&D expenses came to $5.1 million, down from $8.4 million in the fourth quarter of last year.

As of Dec. 31, 2003, the company had $36.6 million in cash, cash equivalents and securities available for sale.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.